Marea Therapeutics raises $190M in debut, targeting overlooked ANGPTL4 in cardiometabolics

A Third Rock Ventures-incubated startup called Marea Therapeutics debuted Tuesday with $190 million to advance a drug for a genetic target for cardiometabolic diseases.

The San Francisco-based biotech has licensed a Novartis antibody targeting ANGPTL4, a gene long tied to risk of heart disease and cardiac events, which is already in a Phase 2 study. Josh Lehrer joined as CEO in October after leading gene-editing startup Graphite Bio, and Ethan Weiss is Marea’s chief scientific officer and a co-founder — having shut down his University of California, San Francisco lab in 2022 to work full-time on the company.

“This is the first time I’ve ever had a paycheck that doesn’t come from the University of California,” said Weiss, who came to UCSF 26 years ago and is still treating patients at its hospital as he jumps into the biotech industry for the first time.

Marea started out of a pandemic-era…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks